[Natalizumab for recurrent-remitting and JC virus seropositive multiple sclerosis]

Itkin B, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A.
Record ID 32018001464
Original Title: Natalizumab en esclerosis múltiple recurrente remitente y seropositividad para el virus JC
Authors' recomendations: CONCLUSIONS High-quality evidence shows that in patients with relapsing-remitting multiple sclerosis (RRMS), natalizumab treatment reduces the number of relapses, the risk of neurological disability progression and the number of active lesions on magnetic resonance imaging compared to placebo, assuming that the effectiveness of natalizumab in patients who have anti-JC virus antibody-positive status is similar to that of the general RRMS population. Moderate-quality evidence suggests that the anti-JC virus antibody index is useful to stratify the risk of developing progressive multifocal leukoencephalopathy in natalizumab treated patients not previously exposed to immunosuppressive drugs, along with the clinical data. Most of expert consensuses and clinical practice guidelines consulted do not consider anti-JC virus antibody-positive status or the anti-JC virus antibody index >1.5 as absolute contraindications for natalizumab therapeutic use and they recommend to adapt safety monitoring protocols to the risk. Public and private sponsors in high-income countries reimburse natalizumab, although many of them restrict its coverage to patients with severe rapidly evolving disease and/or with disease progression to two or more drugs. In Latin America, most public health sponsors do not provide coverage for natalizumab for RRMS.
Project Status: Completed
Year Published: 2018
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Multiple Sclerosis
  • Multiple Sclerosis, Relapsing-Remitting
  • Natalizumab
  • Drug Therapy
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.